Kirin Holdings’ health science-focused arm Kyowa Hakko says the versatility and stability of its postbiotic ingredient has enabled it to continue to enjoy commercial success beyond the surge of COVID-19.
The opportunities in postbiotic development and application are abundant, yet challenges including regulatory policies, consumer awareness and even the definition of postbiotics need to be overcome before the sector can truly realise its full potential.
Japanese firm Kirin is expanding its presence in South East Asia with its flagship postbiotic ingredient, with collaborations with major dairy companies underway.
The supplementation of citicoline has shown to significantly improve episodic and overall memory in older adults, according to a 12-week RCT funded by Kyowa Hakko Bio.
Kirin subsidiary Kyowa Hakko Bio will manufacture and supply three human milk oligosaccharides (HMOs) at its new Thailand facility by 2022 – both for its parent company and the wider market.